ArticleFrontiers in cell and developmental biology2026
AC005034.3/hsa-miR-126-5p/EIF3H axis: bioinformatics analysis, expression validation, and association with prognosis and immunosuppressive microenvironment in pancreatic adenocarcinoma.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic adenocarcinoma (PAAD) ranks among the most lethal human solid tumors, distinguished by its swift progression and limited effective treatment options. The eukaryotic translation initiation factor 3 subunit H (EIF3H) is postulated to be a critical factor in translational initiation, with emerging research indicating its potential involvement in promoting tumor invasion and metastasis. Nevertheless, the precise role of EIF3H within tumors remains insufficiently understood. Methods and Results: Employing a comprehensive pan-cancer methodology, we conducted an analysis of datasets from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), ArrayExpress, and the International Cancer Genome Consortium (ICGC). This analysis systematically assessed the prognostic significance, clinical associations, signaling pathways, immune infiltration profiles, and chemotherapeutic sensitivity associated with EIF3H expression. Through a series of correlation, expression, and survival analyses, we identified noncoding RNAs (ncRNAs) that contribute to the upregulation of EIF3H in pancreatic adenocarcinoma (PAAD). Notably, we identified the AC005034.3/hsa-miR-126-5p axis as the most promising upstream ncRNA-related pathway influencing EIF3H expression in PAAD. The differential expression of these three genes between PAAD and normal pancreatic tissues was further validated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC). Additionally, we demonstrated significant correlations between EIF3H expression and immune infiltration profiles, as well as chemotherapeutic sensitivity in PAAD. Furthermore, we constructed a protein-protein interaction (PPI) network and performed functional annotations involving EIF3H. Conclusion: Our findings indicate that ncRNA-driven overexpression of EIF3H is associated with poor prognosis and tumor immune cell infiltration in PAAD, suggesting that the AC005034.3/hsa-miR-126-5p/EIF3H axis may serve as a promising prognostic biomarker and therapeutic target in PAAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.